Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoglobulin-like domain-containing receptor 2 (ILDR2)
- Target
- ILDR2
- Molecular classification
- Receptor, B7 family immunomodulatory receptor, Type I transmembrane protein
01
Overview
Immunoglobulin-like domain-containing receptor 2 (ILDR2) is a type I transmembrane protein that functions as a member of the B7 family of immunomodulatory receptors. It is involved in the negative regulation of T-cell activation, contributing to immune tolerance. ILDR2 is expressed in several non-lymphoid tissues, fibroblastic reticular cells in lymph nodes, and is important for immune cell recruitment. Pharmacological targeting of ILDR2, for example with the antibody BAY 1905254, promotes T-cell activation and anti-tumor immunity, and has shown potential efficacy in cancer and autoimmune disease models. ILDR2 also participates in epithelial tight junction integrity and may influence inner ear development and function.
- Other names
- C1orf32Angulin-3LISCH-likedJ782G3.1immunoglobulin like domain containing receptor 2ILDR2angulin-3
02
Mechanism of action
Immune checkpoint blockade: antibody inhibition of ILDR2 lifts the immunosuppressive signal to promote T-cell activation, proliferation, and cytotoxicity
03
Biological functions
Negative regulation of T-cell activation (immunosuppressive effect)Recruitment of MARVELD2/tricellulin to tricellular tight junctions in epithelial barrierPotential regulation of alternative pre-mRNA splicing in the inner earInvolvement in ER stress pathways, lipid homeostasis, insulin secretion (by similarity, less direct evidence)
04
Disease associations
Cancer (therapeutic target for immunotherapy)Autoimmune diseases (multiple sclerosis, rheumatoid arthritis, type I diabetes)Deafness (Autosomal recessive forms)
05
Safety considerations
Immune modulation may involve risks similar to other immune checkpoint targets, though specific adverse events are not well-characterized for ILDR2 blockade
06
Interacting drugs
BAY 1905254 (clinical-stage immune checkpoint inhibitor antibody targeting ILDR2 for cancer immunotherapy)
07
Biomarkers
ILDR2 expression levels in tissues, correlation with mutational load and immunogenicity of cancer models
Beyond the preview
Go deeper on Immunoglobulin-like domain-containing receptor 2 (ILDR2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Immunoglobulin-like domain-containing receptor 2 (ILDR2).